- Home
- Publications
- Publication Search
- Publication Details
Title
IDO Targeting in Sarcoma: Biological and Clinical Implications
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-03-05
DOI
10.3389/fimmu.2020.00274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Therapeutic blockade of activin-A improves NK cell function and antitumor immunity
- (2019) Jai Rautela et al. Science Signaling
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- PD-1 inhibition in sarcoma still needs investigation
- (2018) Maud Toulmonde et al. LANCET ONCOLOGY
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
- (2018) Brian W. Labadie et al. CLINICAL CANCER RESEARCH
- Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
- (2018) Biagio Ricciuti et al. PHARMACOLOGY & THERAPEUTICS
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy
- (2017) Dan Ou et al. OncoImmunology
- Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
- (2015) Sandra P. D’Angelo et al. HUMAN PATHOLOGY
- Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
- (2015) Danielle M. Lussier et al. JOURNAL OF IMMUNOTHERAPY
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- PDL1 expression is an independent prognostic factor in localized GIST
- (2015) François Bertucci et al. OncoImmunology
- Programmed Cell Death Ligand 1 Expression in Osteosarcoma
- (2014) J. K. Shen et al. Cancer Immunology Research
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition
- (2013) Vickie Y. Jo et al. PATHOLOGY
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4
- (2012) Jun Cui et al. NATURE IMMUNOLOGY
- Trends in survival for patients with metastatic soft-tissue sarcoma
- (2010) Antoine Italiano et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search